Galleri Blood Test Nears FDA Approval Amid Debate Over Clinical Value

Key points

• The FDA advisory committee endorsed Galleri in September by a 6-4 margin, paving the way for potential approval early next year.
• The test costs approximately $949 and is currently not covered by most private insurance or Medicare, though new laws may enable Medicare coverage by 2028.
• Clinical trials show conflicting results: the UK’s NHS-Galleri trial failed to significantly reduce late-stage diagnoses, while the US Pathfinder 2 trial showed a fourfold increase in cancer detection when paired with standard screenings.
• The test has a low false-positive rate of 0.4% but variable sensitivity, with some experts warning that false negatives could provide a false sense of security.
• Galleri is intended for adults aged 50 and older and must be used alongside existing single-cancer screenings, not as a replacement.

Background

In late September 2026, an FDA advisory panel narrowly endorsed Grail’s Galleri test despite divided opinions on its efficacy. This followed the release of the NHS-Galleri trial results, which showed mixed outcomes for reducing late-stage cancer diagnoses. The current debate centers on whether the test’s ability to detect cancers without standard screening protocols justifies its cost and potential for misuse.

How outlets are covering it

The Washington Post highlights the personal anxiety and uncertainty surrounding the test, noting that while it offers peace of mind for some, it can also trigger excessive worry due to false positives. MedTech Dive emphasizes the technical limitations, with Dr. Elizabeth O’Donnell pointing out that episode sensitivity remains low at 30-40%, meaning many cancers are missed. The Cancer Letter criticizes the FDA for sidestepping questions of clinical benefit, with NCI Director Anthony Letai expressing concern that the test’s performance is overestimated. While proponents like Kevin Oeffinger argue the test catches cancers missed by standard protocols, skeptics like David Tendler warn that marketing is outpacing the science.

Why it matters

The approval of Galleri could reshape cancer screening strategies for millions of Americans, potentially leading to earlier diagnoses for cancers like pancreatic and ovarian, which lack routine screening tests. However, the lack of proven mortality reduction and the high cost raise questions about its value and potential to strain healthcare resources. As insurance coverage expands, the test’s impact on patient outcomes and healthcare systems will be closely monitored.

What to watch

The FDA is expected to make a final decision on Galleri’s approval in early 2027. If approved, the test may see broader insurance coverage, including Medicare, starting in 2028. Ongoing research will focus on long-term data to determine if the test reduces cancer mortality and improves patient outcomes.